Results 181 to 190 of about 106,775 (245)

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]

OTO Open
Sciscent BY, Eberly HW, Lorenz FJ, Goldrich D, Goyal N, Goldenberg D.   +5 more
europepmc   +1 more source

Signals arising from the gastrointestinal tract that affect food intake (Syömiseen vaikuttavat mahasuolikanavan signaalit) [PDF]

Purhonen, Anna-Kaisa
core  

Glucagon-like peptide-1 receptor agonists as potential preventive and therapeutic agents in ischemic stroke

Muhammad Ali, Meng Yang, Sarah Eide, Hong‐Shuo Sun, Tianru Jin, Zhong‐Ping Feng   +5 more
openalex   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. [PDF]

Cureus
Graczyk NA, Bisschops J.
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: A New Era in Cardiometabolic and Cardiovascular Care

Masih Tajdini
openalex   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives. [PDF]

Int J Mol Sci
Gong X, Örge FH.
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Risk of Thyroid Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Dena Osama Khawandanah, Faris F. Alyamani, Bader R. Almutairi, Basil A. Almutairi, Reham Mohammed Alharbi, Shahad Alghanmi, Mohammed T. Alsouri, ABDULAALI R. ALMUTAIRI   +7 more
openalex   +1 more source

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

JAMA Netw Open
Sørensen KK, Møller FT, Yazdanfard PDW, Hasselbalch R, Kragholm KH, Andersen MP, Torp-Pedersen C.   +6 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity. [PDF]

ESC Heart Fail
Raveendra K, Joseph T, Kang J, Hurdus B, Cutting U, Haris M, Younsi T, Aslam A, Petrie M, Metra M, Ajjan RA, Wu J, Gale CP, Nadarajah R.   +13 more
europepmc   +1 more source